CYP2D6基因多态性对慢性肾脏疾病合并高血压患者使用美托洛尔疗效的影响(3)
[2]Parikh N I，Hwang S J，Larson M G，et al.Cardiovascular disease risk factors in chronic kidney disease：overall burden and rates of treatment and control[J].Archives of Internal Medicine，2006，166(17)：1884.
[3]Foundation N K.KDOQI clinical practice guidelines for chronic kidney disease：evaluation，classification，and stratification[J].American Journal of Kidney Diseases the Official Journal of the National Kidney Foundation，2002，39(2 Suppl 1)：S1-266.
[4]朱志慧，李树春，徐斯凡.药物代谢酶CYP2D6基因多态性及表型的研究进展[J].国际遗传学杂志，2009，32(5)：354-359.
[5]Ramu P.Gly460Trp polymorphism of the ADD1 gene and essential hypertension in an Indian population：a meta-analysis on hypertension risk[J].Indian Journal of Human Genetics，2010，16(1)：8.
[6]孙忠实.药物基因组学与受体阻滞剂的合理应用[J].中华高血压杂志，2011，19(5)：409-412.
[7]Rau T，Wuttke H，Michels L M，et al.Impact of the CYP2D6 Genotype on the Clinical Effects of Metoprolol：A Prospective Longitudinal Study[J].Clinical Pharmacology&Therapeutics，2009，85(3)：269-272.
[8]Hcht C，Bertera F M，Mayer M A，et al.Issues in drug metabolism of major antihypertensive drugs：beta-blockers， calcium channel antagonists and angiotensin receptor blockers[J].Expert Opinion on Drug Metabolism&Toxicology，2010，6(2)：199.
[9]Sehrt D，Meineke I，Tzvetkov M，et al.Carvedilol pharmacokinetics and pharmacodynamics in relation to CYP2D6 and ADRB pharmacogenetics[J].Pharmacogenomics，2011，12(6)：783-795.
[10]Raimundo S，Toscano C，Klein K，et al.A novel intronic mutation， 2988G>A，with high predictivity for impaired function of cytochrome P450 2D6 in white subjects[J].Clinical Pharmacology&Therapeutics， 2004，76(2)：128-138.
[11]Andersson T，Flockhart D A，Goldstein D B，et al.Drug-metabolizing enzymes：evidence for clinical utility of pharmacogenomic tests[J].Clinical Pharmacology&Therapeutics，2006，78(6)：559-581.
[12]Wang Y，Zhou L，Dutreix C，et al.Effects of imatinib(Glivec)on the pharmacokinetics of metoprolol，a CYP2D6 substrate，in Chinese patients with chronic myelogenous leukaemia[J].British Journal of Clinical Pharmacology，2008，65(6)：885.
編辑/倪冰冰, 百拇医药(代留玲 茶春丽 李靖娟 陈国姝 李俊)
[3]Foundation N K.KDOQI clinical practice guidelines for chronic kidney disease：evaluation，classification，and stratification[J].American Journal of Kidney Diseases the Official Journal of the National Kidney Foundation，2002，39(2 Suppl 1)：S1-266.
[4]朱志慧，李树春，徐斯凡.药物代谢酶CYP2D6基因多态性及表型的研究进展[J].国际遗传学杂志，2009，32(5)：354-359.
[5]Ramu P.Gly460Trp polymorphism of the ADD1 gene and essential hypertension in an Indian population：a meta-analysis on hypertension risk[J].Indian Journal of Human Genetics，2010，16(1)：8.
[6]孙忠实.药物基因组学与受体阻滞剂的合理应用[J].中华高血压杂志，2011，19(5)：409-412.
[7]Rau T，Wuttke H，Michels L M，et al.Impact of the CYP2D6 Genotype on the Clinical Effects of Metoprolol：A Prospective Longitudinal Study[J].Clinical Pharmacology&Therapeutics，2009，85(3)：269-272.
[8]Hcht C，Bertera F M，Mayer M A，et al.Issues in drug metabolism of major antihypertensive drugs：beta-blockers， calcium channel antagonists and angiotensin receptor blockers[J].Expert Opinion on Drug Metabolism&Toxicology，2010，6(2)：199.
[9]Sehrt D，Meineke I，Tzvetkov M，et al.Carvedilol pharmacokinetics and pharmacodynamics in relation to CYP2D6 and ADRB pharmacogenetics[J].Pharmacogenomics，2011，12(6)：783-795.
[10]Raimundo S，Toscano C，Klein K，et al.A novel intronic mutation， 2988G>A，with high predictivity for impaired function of cytochrome P450 2D6 in white subjects[J].Clinical Pharmacology&Therapeutics， 2004，76(2)：128-138.
[11]Andersson T，Flockhart D A，Goldstein D B，et al.Drug-metabolizing enzymes：evidence for clinical utility of pharmacogenomic tests[J].Clinical Pharmacology&Therapeutics，2006，78(6)：559-581.
[12]Wang Y，Zhou L，Dutreix C，et al.Effects of imatinib(Glivec)on the pharmacokinetics of metoprolol，a CYP2D6 substrate，in Chinese patients with chronic myelogenous leukaemia[J].British Journal of Clinical Pharmacology，2008，65(6)：885.
編辑/倪冰冰, 百拇医药(代留玲 茶春丽 李靖娟 陈国姝 李俊)
参见：首页 > 医疗版 > 疾病专题 > 泌尿外科 > 肾脏